A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114

Project: Research project

Project Details

StatusFinished
Effective start/end date2/8/178/7/20

Funding

  • Merck and Company: $8,600.00